| Name | Title | Contact Details |
|---|---|---|
Ravindra Pateria |
Director of Technology Solutions | Profile |
Natasha Brown |
Associate Director of Information Technology | Profile |
Viracta is focused on advancing a proprietary viral gene activation therapy to address cancers associated with the Epstein-Barr Virus, and will pursue opportunities to address other serious virus-associated disease.
We are a clinical-stage drug discovery and development company advancing innovative therapies to significantly advance the current standard of treatment for serious unmet medical needs.
Clontech Laboratories, Inc. develops, produces, and markets innovative biological products to the life science market worldwide. Clontech is a wholly owned subsidiary of Takara Bio, Inc. Learn more about latest Clontech technologies:
Ocera Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of OCR-002 (ornithine phenylacetate). OCR-002 is an ammonia scavenger and has been granted orphan drug designation and Fast Track status by the U.S. Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic encephalopathy in patients with acute liver failure and acute-on-chronic liver disease.
Inceptor Bio is developing multiple next-generation cell therapy platforms to cure difficult-to-treat cancers with a focus on novel mechanisms to enhance immune cell performance in the tumor microenvironment.